Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2008 2
2009 1
2012 1
2013 1
2014 1
2015 1
2016 3
2017 2
2018 1
2019 5
2021 1
2022 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Benralizumab for the Prevention of COPD Exacerbations.
Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, Sin DD, Vogelmeier CF, Sciurba FC, Bafadhel M, Backer V, Kato M, Ramírez-Venegas A, Wei YF, Bjermer L, Shih VH, Jison M, O'Quinn S, Makulova N, Newbold P, Goldman M, Martin UJ; GALATHEA Study Investigators; TERRANOVA Study Investigators. Criner GJ, et al. N Engl J Med. 2019 Sep 12;381(11):1023-1034. doi: 10.1056/NEJMoa1905248. Epub 2019 May 20. N Engl J Med. 2019. PMID: 31112385 Clinical Trial.
One-year clinical outcomes of transcatheter aortic valve implantation with the latest iteration of self-expanding or balloonexpandable devices: insights from the OPERA-TAVI registry.
Costa G, Saia F, Pilgrim T, Abdel-Wahab M, Garot P, Sammartino S, Gandolfo C, Branca L, Latib A, Amat-Santos I, Mylotte D, De Marco F, De Backer O, Nombela Franco L, Akodad M, Ribichini FL, Bedogni F, Mazzapicchi A, Tomii D, Laforgia P, Cannata S, Fiorina C, Scotti A, Fezzi S, Criscione E, Poletti E, Mazzucca M, Lunardi M, Mainardi A, Andreaggi S, Quagliana A, Montarello NJ, Hennessey B, Mon-Noboa M, Meier D, Adamo M, Sgroi C, Reddavid CM, Strazzieri O, Crescenzia Motta S, Frittitta V, Dipietro E, Comis A, Melfa C, Calì M, Laterra G, Thiele H, Webb JG, Sondergaard L, Tamburino C, Barbanti M. Costa G, et al. EuroIntervention. 2024 Jan 1;20(1):95-103. doi: 10.4244/EIJ-D-23-00720. EuroIntervention. 2024. PMID: 37982161 Free article.
The primary composite endpoint did not differ between patients receiving PRO or ULTRA devices (Kaplan-Meier [KM] estimates 14.0% vs 11.9%; log-rank p=0.27). Patients receiving PRO devices had higher rates of 1-year disabling stroke (KM estimates 2.6% vs 0.4%; log-rank p=0. …
The primary composite endpoint did not differ between patients receiving PRO or ULTRA devices (Kaplan-Meier [KM] estimates 14.0% vs 1 …
Risk and Timing of Noncardiac Surgery After Transcatheter Aortic Valve Implantation.
Okuno T, Demirel C, Tomii D, Erdoes G, Heg D, Lanz J, Praz F, Zbinden R, Reineke D, Räber L, Stortecky S, Windecker S, Pilgrim T. Okuno T, et al. JAMA Netw Open. 2022 Jul 1;5(7):e2220689. doi: 10.1001/jamanetworkopen.2022.20689. JAMA Netw Open. 2022. PMID: 35797045 Free PMC article.
Composite end points occurred within 30 days of surgery among 58 patients (Kaplan-Meier estimate, 19.7%; 95% CI, 15.6%-24.7%). There were no significant differences in baseline demographics between patients with the 30-day composite end point and 242 patients without this …
Composite end points occurred within 30 days of surgery among 58 patients (Kaplan-Meier estimate, 19.7%; 95% CI, 15.6%-24.7%). There …
Dissociated response and clinical benefit in patients treated with nivolumab monotherapy.
Sato Y, Morimoto T, Hara S, Nagata K, Hosoya K, Nakagawa A, Tachikawa R, Tomii K. Sato Y, et al. Invest New Drugs. 2021 Aug;39(4):1170-1178. doi: 10.1007/s10637-021-01077-7. Epub 2021 Feb 10. Invest New Drugs. 2021. PMID: 33566254
We investigated treatment outcome and compared overall survival using the Kaplan-Meier Method and log-rank tests. Further, we conducted the same analysis in patients who had previously received chemotherapy or tyrosine kinase inhibitor therapy in our hospital. ...
We investigated treatment outcome and compared overall survival using the Kaplan-Meier Method and log-rank tests. Further, we conduct …
The impact of lymphadenectomy on lymph node recurrence after performing various treatments for esophageal squamous cell carcinoma.
Shigeno T, Hoshino A, Matsunaga S, Shimano R, Ishibashi N, Shinohara H, Shiobara H, Tomii C, Saito K, Fujiwara N, Sato Y, Kawada K, Tokunaga M, Kinugasa Y. Shigeno T, et al. BMC Surg. 2022 May 11;22(1):171. doi: 10.1186/s12893-022-01618-8. BMC Surg. 2022. PMID: 35545769 Free PMC article.
Overall survival (OS) and recurrence-free survival (RFS) after lymphadenectomy were calculated by the Kaplan-Meier method. We also used a univariate analysis with a Cox proportional hazards model to determine factors influencing the long-term outcomes. ...
Overall survival (OS) and recurrence-free survival (RFS) after lymphadenectomy were calculated by the Kaplan-Meier method. We also us …
Severe or life-threatening asthma exacerbation: patient heterogeneity identified by cluster analysis.
Sekiya K, Nakatani E, Fukutomi Y, Kaneda H, Iikura M, Yoshida M, Takahashi K, Tomii K, Nishikawa M, Kaneko N, Sugino Y, Shinkai M, Ueda T, Tanikawa Y, Shirai T, Hirabayashi M, Aoki T, Kato T, Iizuka K, Homma S, Taniguchi M, Tanaka H. Sekiya K, et al. Clin Exp Allergy. 2016 Aug;46(8):1043-55. doi: 10.1111/cea.12738. Epub 2016 May 24. Clin Exp Allergy. 2016. PMID: 27041475
Evaluation of objective nutritional indexes as predictors of one-year outcomes after transcatheter aortic valve implantation.
Okuno T, Koseki K, Nakanishi T, Sato K, Ninomiya K, Tomii D, Tanaka T, Sato Y, Horiuchi Y, Koike H, Yahagi K, Komiyama K, Tanaka J, Aoki J, Yokozuka M, Miura S, Tanabe K. Okuno T, et al. J Cardiol. 2019 Jul;74(1):34-39. doi: 10.1016/j.jjcc.2019.02.017. Epub 2019 Mar 28. J Cardiol. 2019. PMID: 30929930 Free article.
According to the cut-off values, we investigated the association of these indexes with 1-year clinical outcomes including all-cause mortality and re-hospitalization due to heart failure. RESULTS: In the Kaplan-Meier analysis, patients with a higher CONUT score and lower PN …
According to the cut-off values, we investigated the association of these indexes with 1-year clinical outcomes including all-cause mortalit …
Early depth of tumor shrinkage and treatment outcomes in non-small cell lung cancer treated using Nivolumab.
Kawachi H, Fujimoto D, Morimoto T, Hosoya K, Sato Y, Kogo M, Nagata K, Nakagawa A, Tachikawa R, Tomii K. Kawachi H, et al. Invest New Drugs. 2019 Dec;37(6):1257-1265. doi: 10.1007/s10637-019-00770-y. Epub 2019 Apr 1. Invest New Drugs. 2019. PMID: 30937690
Tumor assessments followed the Response Evaluation Criteria in Solid Tumors (RECIST). Using Kaplan-Meier and receiver operating characteristic (ROC) curve analyses, treatment outcomes were compared with percent tumor reductions from baseline to the first evaluation (8-12 w …
Tumor assessments followed the Response Evaluation Criteria in Solid Tumors (RECIST). Using Kaplan-Meier and receiver operating chara …
Concordance between the response evaluation criteria in solid tumors version 1.1 and the immune-related response criteria in patients with non-small cell lung cancer treated with nivolumab: a multicenter retrospective cohort study.
Kataoka Y, Hirano K, Narabayashi T, Hara S, Fujimoto D, Tanaka T, Ebi N, Tomii K, Yoshioka H. Kataoka Y, et al. Cancer Chemother Pharmacol. 2018 Feb;81(2):333-337. doi: 10.1007/s00280-017-3498-z. Epub 2017 Dec 11. Cancer Chemother Pharmacol. 2018. PMID: 29230503
21 results